CTRI/2011/06/001835已完成2 期
The efficacy of the SIDDHA MANDOORAM [internal] in the treatment of PITHA PANDU [Iron Defeciency Anaemia]
ational Institute of Siddha Tambaram SanatoriumDepartment of AYUSH Chennai Tamil Nadu0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •patient willing to undergo blood investigation;
- •Clinical symptoms of:
- •Breathlessness
- •Palpitation
- •Koilonychias etc;
- •Hemoglobin level less than normal range ie.,7-13 mg/dl for men,7-10mg/dl for women[Normal range:Male:14-18gms/dl;Female:11-15gms/dl]Patient blood smear showing Microcytic Hypochromic RBC;
- •Patient willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 48 days but can be opt out of the trial of his/her own conscious discretion
排除标准
- •Parasitic infection;Bleeding disorder[Bleeding piles,Menorrhagia];Pregnancy and lactation;Presence of any associated severe systemic illness[e.g RA,CA];Endocrine disorder[thyroid abnormality,Diabetes mellitus];cardiac disease;Renal disease; H/o of steriod exposure for prolonged time;Peptic ulcer;Gasterctomy;Inherited defects[sickle cell anaemia,Thalassemia];Malabsorption syndrome;Patient not willing to give blood sample.
研究者
相似试验
招募中
2 期
A CLINICAL TRIAL ON SIDDHA FORMULATION THETRAN VITHAI KUDINEER CHOORANAM FOR MADHUMEGAMCTRI/2019/05/019362AyothidossPandithar Hospital
尚未招募
3 期
Evaluating therapeutic efficacy of VASANTHAKUSUMAKARAM MATHIRAI for PITHA NEER CHURUKU(Urinary Tract Infection)CTRI/2023/03/050696ational Institute Of Siddha
招募中
2 期
STUDY ON MADHUMEGAM [TYPE 2 DIABETES MELLITUS] WITH SIDDHA MEDICINE ULOGA CHENDURAM AND OIL BATH ASHWAGANDHATHI THAILAMCTRI/2019/10/021833ational Institute Of Siddha
尚未招募
2 期
Assessing the efficacy of Siddha medicines given for Lumbar Spondylosis patientsCTRI/2021/12/038558Government siddha medical college
已完成
2 期
START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19)ISRCTN13311119Eminentlabs GmbH116
